WO2016080510A1 - 新規二重特異的抗体フォーマット - Google Patents
新規二重特異的抗体フォーマット Download PDFInfo
- Publication number
- WO2016080510A1 WO2016080510A1 PCT/JP2015/082653 JP2015082653W WO2016080510A1 WO 2016080510 A1 WO2016080510 A1 WO 2016080510A1 JP 2015082653 W JP2015082653 W JP 2015082653W WO 2016080510 A1 WO2016080510 A1 WO 2016080510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- light chain
- bispecific antibody
- heavy chain
- variable region
- antibody
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Definitions
- the present invention relates to a novel bispecific antibody and a method for producing the same.
- a bispecific antibody is an antibody that recognizes two different antigens and contains the heavy chain variable region and the light chain variable region of two antibodies against each antigen.
- Various formats (structures) have been reported for bispecific antibodies (Exp. Rev. Clin. Pharmacol., Vol. 3, No. 4, p. 491, 2010). For example, (1) the heavy chain variable region of one antibody and the carboxy terminus (C terminus) of the light chain variable region of the other antibody via a linker on the amino terminal (N terminal) side of the heavy chain and the light chain, Ligated tetravalent bispecific antibody (also referred to as DVD-Ig. Patent Document 1), (2) The heavy chain and light chain of each antibody were joined via CH3 by the knobs-into-holes technique.
- Bivalent bispecific antibody (WO1998 / 050431), (3) The C-terminus of scFv of the other antibody is linked to the N-terminus of the heavy chain or light chain of one antibody via a linker, or one A tetravalent bispecific antibody (Nat. Biotechnol., Vol. 15, No. 15), in which the N-terminus of the scFv of the other antibody is linked to the C-terminus of the heavy chain or light chain of the other antibody via a linker. 2, p.1 9,1997) and the like have been reported.
- a format in which the variable region of another IgG type antibody is linked to the N-terminal side of one IgG type antibody such as the format of (1) above. Is easy to maintain the antigen-binding ability of the variable region of the linked outer (N-terminal side) antibody, and is suitable for preparing bispecific antibodies of various antibody combinations.
- the affinity between the variable region located inside (C-terminal side) and the corresponding antigen tends to decrease (Non-Patent Document 1).
- One means for recovering from this decrease in affinity includes the use of a linker having a long amino acid length and the use of a flexible linker sequence (Patent Document 1).
- Non-Patent Document 1 Non-Patent Document 1
- the structure between the heavy chain variable region on the outer side (N-terminal side) and the light chain variable region cannot be maintained due to enzymatic cleavage, and stability is lowered.
- the linker cleaving step after antibody purification leads to complication of the antibody production process and a decrease in antibody yield.
- the object of the present invention is to provide a bispecific antibody in a novel format that retains high binding ability to two different antigens and can be efficiently produced in a commercial production process.
- the present invention may include the following inventions.
- a bispecific antibody comprising two heavy chains, two first light chains, and two second light chains;
- the heavy chain includes, in order from the amino terminal side, a first heavy chain variable region, a CH1 region, a first linker, a second heavy chain variable region, and a heavy chain constant region
- the first light chain includes, in order from the amino terminal side, a first light chain variable region and a first light chain constant region
- the second light chain includes, in order from the amino terminal side, a second light chain variable region and a second light chain constant region
- the first heavy chain variable region and the first light chain variable region form a first antigen binding site;
- the second heavy chain variable region and the second light chain variable region form a second antigen binding site;
- the first antigen binding site and the second antigen binding site recognize different antigens; Bispecific antibody.
- [4] A method for producing a bispecific antibody the method comprising culturing the host cell according to [2] and expressing the bispecific antibody.
- [6] A method for producing a bispecific antibody the method comprising culturing the host cell according to [3] and expressing the bispecific antibody.
- a bispecific antibody that can be produced by the method according to [6] or [7].
- the antigen-binding fragment according to [9] which is Fab, Fab ′, or F (ab ′) 2 .
- a bispecific antibody comprising two light chains, two fragments of a first heavy chain, and two second heavy chains;
- the light chain comprises, in order from the amino terminal side, a first light chain variable region, a first light chain constant region, a first linker, a second light chain variable region, and a second light chain constant region.
- Each fragment of the first heavy chain includes, in order from the amino terminal side, the first heavy chain variable region and the CH1 region,
- the second heavy chain includes a second heavy chain variable region and a heavy chain constant region, respectively, in order from the amino terminal side,
- the first heavy chain variable region and the first light chain variable region form a first antigen binding site;
- the second heavy chain variable region and the second light chain variable region form a second antigen binding site;
- the first antigen binding site and the second antigen binding site recognize different antigens; Bispecific antibody.
- a method for producing a bispecific antibody comprising culturing the host cell according to [12] and expressing the bispecific antibody.
- a method for producing a bispecific antibody comprising culturing the host cell according to [13] and expressing the bispecific antibody.
- bispecific antibody of the novel format of the present invention retains high binding ability to two different antigens and can be efficiently produced in a commercial production process.
- Examples of the structure of the bispecific antibody of the present invention (tandem forms a and b) and examples of the structure of the reference bispecific antibody (tandem form c, tandem form d and DVD-Ig form b) are shown.
- VH (1) and VL (1) indicate the first heavy chain variable region and the first light chain variable region
- VH (2) and VL (2) indicate the second heavy chain variable region.
- restoration SDS-PAGE analysis of tandem form a and c is shown.
- band 1 represents a heavy chain
- band 2 represents an uncut light chain (light chain fragment)
- bands 3 and 4 represent each light chain generated by linker cleavage with a protease.
- the basic structure of antibody molecules is the same for each class, with a heavy chain with a molecular weight of 50,000 to 70,000 and a light chain with 20,000 to 30,000. Consists of The heavy chain is usually composed of a polypeptide chain containing about 440 amino acids, has a characteristic structure for each class, and corresponds to IgG, IgM, IgA, IgD, IgE, Ig ⁇ , Ig ⁇ , Ig ⁇ , Ig ⁇ . It is called.
- IgG has IgG1, IgG2, IgG3, and IgG4 subclasses, and the corresponding heavy chains are called Ig ⁇ 1, Ig ⁇ 2, Ig ⁇ 3, and Ig ⁇ 4.
- the light chain is usually composed of a polypeptide chain containing about 220 amino acids, and two types of L-type and K-type are known, and are called Ig ⁇ and Ig ⁇ , respectively.
- the peptide structure of the basic structure of an antibody molecule has a molecular weight of 150,000 to 190,000, in which two heavy chains and two light chains that are homologous are linked by a disulfide bond (SS bond) and a non-covalent bond, respectively. .
- the two light chains can be paired with any heavy chain.
- Each antibody molecule always consists of two identical light chains and two identical heavy chains.
- Ig ⁇ intrachain S—S bonds
- VH heavy chain variable region
- VL light chain variable region
- the amino acid sequence on the carboxy terminal (C terminal) side of the variable region is almost constant for each class or subclass and is called a constant region, and each domain has a heavy chain constant region (CH) and a light chain constant region (CL). It is called.
- the heavy chain constant region (CH) is further divided into three regions of CH1, CH2, and CH3 from the N-terminal side.
- a region between the CH1 region and the CH2 region of the heavy chain constant region of the antibody is called a hinge region, and is involved in the mobility of the structure composed of the heavy chain variable region and the CH1 region.
- the bispecific antibody of the present invention includes the bispecific antibody described in the following (1) and (2): (1) Heavy chain-linked bispecific antibody A bispecific antibody comprising two heavy chains, two first light chains, and two second light chains. Including The heavy chain includes, in order from the amino terminal side, a first heavy chain variable region, a CH1 region, a first linker, a second heavy chain variable region, and a heavy chain constant region, The first light chain includes, in order from the amino terminal side, a first light chain variable region and a first light chain constant region, The second light chain includes, in order from the amino terminal side, a second light chain variable region and a second light chain constant region, The first heavy chain variable region and the first light chain variable region form a first antigen binding site; The second heavy chain variable region and the second light chain variable region form a second antigen binding site; The first antigen binding site and the second antigen binding site recognize different antigens; Bispecific antibody.
- Light chain-linked bispecific antibody A bispecific antibody comprising two light chains, two first heavy chain fragments, and two second heavy antibodies. Including chains, The light chain comprises, in order from the amino terminal side, a first light chain variable region, a first light chain constant region, a first linker, a second light chain variable region, and a second light chain constant region.
- Each fragment of the first heavy chain includes, in order from the amino terminal side, the first heavy chain variable region and the CH1 region,
- the second heavy chain includes a second heavy chain variable region and a heavy chain constant region, respectively, in order from the amino terminal side,
- the first heavy chain variable region and the first light chain variable region form a first antigen binding site;
- the second heavy chain variable region and the second light chain variable region form a second antigen binding site;
- the first antigen binding site and the second antigen binding site recognize different antigens; Bispecific antibody.
- the “bispecific antibody” means an antibody that recognizes two different antigens and includes the heavy chain variable region and the light chain variable region of two antibodies against each antigen.
- “antigen” means any substance (eg, protein) or a portion thereof to which an antibody binds.
- the combination of antigens recognized by the bispecific antibody of the present invention is not limited, and those skilled in the art can, for example, combine two antibodies against different proteins, or a combination of two antibodies that bind to different portions of the same protein. The combination of the two antibodies can be appropriately selected depending on the target therapeutic application.
- FIG. 1 An example of the structure of the bispecific antibody of the present invention is shown in FIG. 1 (tandem forms a and b).
- the first and second heavy chain variable regions and the first and second light chain variable regions used in the bispecific antibody of the present invention include, but are not limited to, human antibodies and humanized antibodies.
- the heavy chain variable region and light chain variable region of any form of antibody can be used.
- the CH1 region of any subclass heavy chain constant region (eg, Ig ⁇ 1, Ig ⁇ 2, Ig ⁇ 3, or Ig ⁇ 4 constant region) can be selected.
- the CH1 region between the first heavy chain variable region and the linker in the heavy chain is the CH1 region of a human Ig ⁇ 1 constant region.
- the heavy chain constant region may be any subclass of heavy chain constant region (eg, Ig ⁇ 1, Ig ⁇ 2, Ig ⁇ 3, or Ig ⁇ 4 constant region), and may be the same as the subclass of the CH1 region. Also good. Preferably, the CH1 region subclass and the heavy chain constant region subclass are the same. In one embodiment, the heavy chain constant region is a human Ig ⁇ 1 constant region.
- any subclass of light chain constant region for example, constant region of Ig ⁇ or Ig ⁇
- they may be the same or different from each other. May be.
- the first light chain constant region and the second light chain constant region are human Ig ⁇ constant regions.
- the first linker links the CH1 region and the second heavy chain variable region for heavy chain linked bispecific antibodies, and the first light chain constant region and the second chain for light chain linked bispecific antibodies.
- Any peptide (peptide linker) can be used as long as it links two light chain variable regions and the bispecific antibody has its function.
- the length and amino acid sequence of the first linker can be appropriately selected by those skilled in the art.
- the first linker is a peptide consisting of at least 5, more preferably at least 10, even more preferably 15-50 amino acids.
- a preferred first linker is a peptide linker (also referred to as a GS linker) comprising the amino acid sequence GlyGlyGlyGlySer (also referred to as (Gly) 4 Ser), preferably a plurality, more preferably 3-5 (Gly 4 Including Ser.
- GlyGlyGlyGlyGlySer also referred to as (Gly) 4 Ser
- An example of the first linker is a peptide linker (also referred to as ((Gly) 4 Ser) 3 ) having an amino acid sequence of amino acid numbers 222 to 236 of SEQ ID NO: 2.
- the bispecific antibody of the present invention has binding activity for two different antigens. Whether or not each antigen has binding activity can be confirmed using a measurement method known in the art. Examples of such measurement methods include methods such as Enzyme-Linked ImmunoSorbent Assay (ELISA) and surface plasmon resonance (SPR) analysis, which are appropriately selected by those skilled in the art depending on the target antigen.
- ELISA Enzyme-Linked ImmunoSorbent Assay
- SPR surface plasmon resonance
- the present invention also includes antigen-binding fragments of the bispecific antibodies of the present invention.
- the antigen-binding fragment of the bispecific antibody of the present invention includes a first and a second heavy chain variable region and a first and a second light chain variable region, and has a binding activity for each two antigens. Refers to a fragment of a specific antibody, and representative antigen-binding fragments include Fab, Fab ′, and F (ab ′) 2 .
- Fab is a heavy chain fragment consisting of the region from the first heavy chain variable region of the heavy chain to a portion of the hinge region of the heavy chain constant region, the first light chain And an antigen-binding fragment of a bispecific antibody comprising a second light chain.
- Fab ′ includes a heavy chain fragment consisting of a region from the first heavy chain variable region of the heavy chain to a part of the hinge region of the heavy chain constant region, the first light chain, and the second light chain. This is an antigen-binding fragment of a bispecific antibody, and the hinge region part contains a cysteine residue constituting an interheavy chain SS bond.
- F (ab ′) 2 is an antigen-binding fragment of a bispecific antibody in which two Fab ′ are linked by an inter-heavy chain SS bond in the hinge region.
- Fab is the light chain (including from the first light chain variable region to the second light chain constant region), the first heavy chain fragment, and the second heavy chain.
- An antigen-binding fragment of a bispecific antibody comprising a heavy chain variable region of the chain and a second heavy chain fragment consisting of the CH1 region of the heavy chain constant region and part of the hinge region.
- Fab ′ refers to the light chain (including from the first light chain variable region to the second light chain constant region), the first heavy chain fragment, and the heavy chain variable region and heavy chain constant of the second heavy chain.
- F (ab ′) 2 is an antigen-binding fragment of a bispecific antibody in which two Fab ′ are linked by an inter-heavy chain SS bond in the hinge region.
- Host cells of the present invention include host cells having the following characteristics: (1) Host cells for producing heavy chain-linked bispecific antibodies The following a) to c): a) a polynucleotide comprising a base sequence encoding the heavy chain of a heavy chain-linked bispecific antibody and a polynucleotide comprising the base sequences encoding the first light chain and the second light chain of the bispecific antibody A host cell transformed with an expression vector comprising: b) an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of a heavy chain-linked bispecific antibody and a base sequence encoding the first light chain and the second light chain of the bispecific antibody A host cell transformed with an expression vector comprising a polynucleotide comprising: and c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of a heavy chain-linked bi
- the polynucleotide comprising the base sequences encoding the first light chain and the second light chain of the bispecific antibody, the carboxy terminus of the first light chain via a second linker, Comprising a base sequence encoding a polypeptide linked to the amino terminus of a second light chain, wherein the second linker is a peptide linker comprising a protease recognition sequence; Host cell.
- (2) Host cells for producing light chain-linked bispecific antibodies The following a) to c): a) a polynucleotide comprising a base sequence encoding the light chain of a light chain-linked bispecific antibody, a fragment of the first heavy chain of the bispecific antibody, and a base sequence encoding the second heavy chain A host cell transformed with an expression vector comprising the polynucleotide; b) encoding an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of a light chain-linked bispecific antibody, a fragment of the first heavy chain of the bispecific antibody, and a second heavy chain A host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence; and c) transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of a light chain-linked bispecific antibody.
- a host cell Selected from a host cell and a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding a first heavy chain fragment and a second heavy chain of the bispecific antibody,
- a host cell a polynucleotide comprising a base sequence encoding a first heavy chain fragment and a second heavy chain of the bispecific antibody is a second linker at the carboxy terminus of the first heavy chain fragment.
- the cell used for producing the host cell of the present invention is compatible with the expression vector to be used and can be transformed with the expression vector to express the bispecific antibody of the present invention, It is not particularly limited.
- the host cell include various cells (eg, animal cells (eg, CHO-K1SV cells), insect cells (eg, CHO-K1SV cells) such as natural cells or artificially established cells usually used in the technical field of the present invention. Sf9), bacteria (eg, Escherichia), yeast (eg, Saccharomyces, Pichia)), preferably cultured cells such as CHO-K1SV cells, CHO-DG44 cells, 293 cells, NS0 cells, etc. Can be used.
- the second linker is a peptide containing a protease recognition sequence (peptide linker).
- the second linker is a first light chain and a second light chain.
- the second linker links the fragment of the first heavy chain and the second heavy chain.
- the length of the second linker can be appropriately selected by those skilled in the art, but preferably, the second linker is a peptide consisting of 5 to 60 amino acids.
- protease recognition sequences known in the art can be used as the protease recognition sequence (J. Biol. Chem., Vol. 283, No. 30, p20897, 2008).
- the protease recognition sequence is an intracellular protease recognition sequence in the host cell.
- intracellular protease recognition sequences include the amino acid sequence shown in SEQ ID NO: 5 (recognized by intracellular proteases Furin, PC7, and PACE4), the amino acid sequence shown in SEQ ID NO: 6 (recognized by PC7 and PACE4), Examples include the amino acid sequence shown in SEQ ID NO: 7 (recognized by Furin) and the amino acid sequence shown in SEQ ID NO: 8 (recognized by Furin).
- the second linker may be a peptide consisting of a protease recognition sequence, or may contain an additional amino acid sequence on the N-terminal side and / or C-terminal side of the protease recognition sequence.
- additional amino acid sequence (Gly) 4 Ser can be mentioned, for example, the second linker comprises one or several (Gly) 4 Ser.
- the second linker include a peptide linker consisting of the amino acid sequence shown in SEQ ID NO: 9, 10, 11, or 12.
- the host cell of the present invention for producing a heavy chain-linked bispecific antibody is a host cell selected from the above (1) a) and b), and the second linker is the host A host cell that is a peptide linker containing an intracellular protease recognition sequence in a cell.
- the host cell of the present invention for producing a light chain-linked bispecific antibody is a host cell selected from the above (2) a) and b), and the second linker is the host A host cell that is a peptide linker containing an intracellular protease recognition sequence in a cell.
- a polynucleotide comprising a sequence, and a polynucleotide comprising a base sequence encoding the fragment of the first heavy chain and the second heavy chain of the bispecific antibody (hereinafter collectively referred to as “polynucleotide of the present invention”) Is a gene synthesis method known in the art (for example, according to the nucleotide sequence designed based on the amino acid sequences of the heavy and light chains of the bispecific antibody and the first and second linkers). , Using synthetic methods) of antibody genes as described in WO
- the expression vector used in the host cell of the present invention includes the present invention in various host cells such as eukaryotic cells (for example, animal cells, insect cells, plant cells, yeast) and / or prokaryotic cells (for example, E. coli).
- the polynucleotide is not particularly limited as long as it can express the polynucleotide and can produce the polypeptide encoded by them.
- Examples of such expression vectors include plasmid vectors, viral vectors (eg, adenovirus, retrovirus) and the like. Examples thereof include pEE6.4 and pEE12.4 (Lonza), AG- ⁇ 1 and AG- ⁇ .
- An expression vector such as (for example, see WO94 / 20632) can be used.
- the expression vector used in the host cell of the present invention may contain a promoter operably linked to the polynucleotide of the present invention.
- a promoter for expressing the polynucleotide in animal cells include virus-derived promoters such as CMV, RSV, SV40, actin promoter, EF (longation factor) 1 ⁇ promoter, heat shock promoter, and the like.
- promoters for expression in bacteria include, for example, trp promoter, lac promoter, ⁇ PL promoter, tac promoter and the like.
- promoters for expression in yeast include GAL1 promoter, GAL10 promoter, PH05 promoter, PGK promoter, GAP promoter, and ADH promoter.
- the expression vector can contain a start codon and a stop codon.
- the expression vector includes an enhancer sequence, 5 ′ and 3 ′ untranslated regions of the polynucleotide of the present invention, a secretory signal sequence, a splicing junction, a polyadenylation site, or a replicable unit. Also good.
- the expression vector can include a start codon, a stop codon, a terminator region, and a replicable unit.
- the expression vector may contain a selection marker (for example, tetracycline resistance gene, ampicillin resistance gene, kanamycin resistance gene, neomycin resistance gene, dihydrofolate reductase gene) that is usually used depending on the purpose.
- a selection marker for example, tetracycline resistance gene, ampicillin resistance gene, kanamycin resistance gene, neomycin resistance gene, dihydrofolate reductase gene
- the method for transforming host cells with an expression vector is not particularly limited, and for example, a calcium phosphate method, an electroporation method, or the like can be used.
- the method for producing a bispecific antibody of the present invention includes a method for producing a bispecific antibody, comprising culturing the host cell of the present invention and expressing the bispecific antibody.
- the culture of the host cell of the present invention can be performed by a known method.
- the culture conditions such as temperature, medium pH, and culture time are appropriately selected.
- the medium include MEM medium (Science, Vol. 130, No. 3373, p. 432, 1959) containing about 5 to 20% fetal bovine serum, DMEM medium (Virology, Vol. 8, No. 3, p. 396, 1959), RPMI 1640 medium (J. Am. Med. Assoc., Vol. 199, No. 8, p. 519, 1967), 199 medium (Exp. Biol. Med , Vol. 73, No. 1, p. 1, 1950) or the like.
- the pH of the medium is preferably about 6 to 8, and the culture is usually carried out at about 30 to 40 ° C. for about 15 to 72 hours with aeration and stirring as necessary.
- the medium include Grace's medium containing fetal bovine serum (Proc. Natl. Acad. Sci. USA, Vol. 82, No. 24, p. 8404, 1985). Can be used.
- the pH of the medium is preferably about 5 to 8, and the culture is usually carried out at about 20 to 40 ° C. for about 15 to 100 hours with aeration and agitation as necessary.
- a liquid medium containing a nutrient source is appropriate.
- the nutrient medium preferably contains a carbon source, an inorganic nitrogen source, or an organic nitrogen source necessary for the growth of transformed host cells.
- the carbon source include glucose, dextran, soluble starch, and sucrose.
- the inorganic nitrogen source or organic nitrogen source include ammonium salts, nitrates, amino acids, corn steep liquor, peptone, casein, and meat extract. , Soybean meal, potato extract and the like.
- other nutrients eg, inorganic salts (eg, calcium chloride, sodium dihydrogen phosphate, magnesium chloride), vitamins, etc.), antibiotics (eg, tetracycline, neomycin, ampicillin, kanamycin, etc.) Good.
- the pH of the medium is preferably about 5-8.
- preferred media include LB medium, M9 medium (Mol. Clo., Cold Spring Harbor Laboratory, Vol. 3, A2.2) and the like. Cultivation is usually carried out at about 14 to 43 ° C. for about 3 to 24 hours with aeration or agitation as necessary.
- yeast for example, a Burkholder minimum medium (Proc. Natl. Acad. Sci. USA, Vol. 77, No. 8, p. 4504, 1980) can be used. Cultivation is usually carried out at about 20 to 35 ° C. for about 14 to 144 hours with aeration and agitation, if necessary.
- the bispecific antibody of the present invention can be expressed.
- the second linker in the host cell of the present invention used is a peptide linker comprising an intracellular protease recognition sequence.
- the host cell of the present invention used to produce a heavy chain linked bispecific antibody is a host cell selected from ⁇ a host cell of the present invention> (1) a) and b) And wherein the second linker is a peptide linker comprising an intracellular protease recognition sequence in the host cell.
- the host cell of the present invention used to produce a light chain linked bispecific antibody is a host cell selected from ⁇ a host cell of the present invention> (2) a) and b) And wherein the second linker is a peptide linker comprising an intracellular protease recognition sequence in the host cell.
- the second linker in the host cell of the present invention to be used is a peptide linker containing an intracellular protease recognition sequence, and the second linker is cleaved by the protease in the host cell in the culture step.
- the method for producing the bispecific antibody of the present invention optionally includes a protease recognition sequence in the second linker.
- the protease treatment step can be performed using a method known in the art depending on the protease recognition sequence to be used. For example, a precision protease recognition sequence (SEQ ID NO: 13) may be used as the protease recognition sequence in the second linker, and treatment with precision protease (GE Healthcare Japan) may be performed after the culturing step.
- the method for producing the bispecific antibody of the present invention includes the step of culturing the host cell of the present invention and expressing the bispecific antibody, and further recovering the bispecific antibody from the host cell. Preferably comprising an isolation or purification step.
- Isolation or purification methods include, for example, methods using solubility such as salting out, solvent precipitation, methods using molecular weight differences such as dialysis, ultrafiltration, gel filtration, ion exchange chromatography, hydroxyapatite chromatography, etc.
- the antibody accumulated in the culture supernatant can be purified by various chromatography, for example, column chromatography using a protein A column or a protein G column.
- the bispecific antibody of the present invention also includes a bispecific antibody that can be produced by the method of producing the bispecific antibody of the present invention.
- concentration mol / L is expressed as M.
- 1M sodium hydroxide aqueous solution means 1 mol / L sodium hydroxide aqueous solution.
- bispecific antibodies were prepared as the bispecific antibodies of the present invention.
- a bispecific antibody comprising a light chain FIG.
- tandem form a 1, referred to as tandem form a
- tandem form b a heavy chain variable region of an anti-human TLR2 antibody of tandem form a and a heavy chain variable of a light chain variable region and an anti-human TLR4 antibody Bispecific antibody in which the region and the light chain variable region are respectively replaced
- the region consisting of the amino acid sequence from amino acid numbers 118 to 221 of SEQ ID NO: 2 is the CH1 region of human Ig ⁇ 1.
- the region consisting of the amino acid sequence from amino acid numbers 222 to 236 of SEQ ID NO: 2 is a linker sequence.
- the region consisting of the amino acid sequence from amino acid numbers 237 to 355 of SEQ ID NO: 2 is the heavy chain variable region of the anti-human TLR4 antibody.
- the region consisting of amino acid sequences from amino acid numbers 356 to 685 of SEQ ID NO: 2 is the heavy chain constant region of human Ig ⁇ 1.
- a signal sequence (Protein, Eng., Vol. 5) of the gene encoding a polypeptide in which the C-terminus of the light chain of the anti-human TLR2 antibody is linked to the N-terminus of the light chain of the anti-human TLR4 antibody via a linker. 1, No. 6, p. 499, 1987), and this light chain polypeptide gene was inserted into the GS vector pEE12.4 (Lonza).
- the base sequence of the gene encoding this light chain polypeptide is shown in SEQ ID NO: 3, and the amino acid sequence encoded thereby is shown in SEQ ID NO: 4.
- the region consisting of the amino acid sequence from amino acid numbers 1 to 108 of SEQ ID NO: 4 is the light chain variable region of the anti-human TLR2 antibody.
- the region consisting of the amino acid sequence from amino acid numbers 109 to 214 of SEQ ID NO: 4 is a constant region of human Ig ⁇ .
- the region consisting of the amino acid sequence from amino acid numbers 215 to 270 of SEQ ID NO: 4 is a linker sequence (SEQ ID NO: 9).
- the region consisting of the amino acid sequence from amino acid numbers 271 to 378 of SEQ ID NO: 4 is the light chain variable region of the anti-human TLR4 antibody.
- the region consisting of the amino acid sequence of amino acid numbers 379 to 484 of SEQ ID NO: 4 is a constant region of human Ig ⁇ .
- the above-described GS vector into which the heavy chain and light chain genes of the bispecific antibody are respectively inserted is digested with NotI and PvuI, and ligation kit Ligation-Convenience Kit (NIPPONGENE) or ligation reagent Ligation-high ( (Toyobo) was used for ligation to construct a GS vector in which both heavy chain and light chain genes were inserted.
- Both heavy chain and light chain expression vectors were transferred to Expi293 293 (Life Technologies) for Expi293 cells (Life Technologies) cultured in Expi293 Expression medium (Life Technologies) at about 3 ⁇ 10 6 cells / mL. And cultured for 7 days. The culture supernatant was purified using a protein A or protein G column (GE Healthcare Japan) to obtain a purified antibody.
- tandem foam b A portion encoding the heavy chain variable region of the anti-human TLR2 antibody (base numbers 1 to 351 of SEQ ID NO: 1) and the heavy chain variable region of the anti-human TLR4 antibody (base of SEQ ID NO: 1) in the base sequence shown in SEQ ID NO: 1
- a heavy chain gene having a base sequence in which numbers 709 to 1065) were replaced was prepared, and a heavy chain GS vector was prepared in the same manner as the tandem form a heavy chain vector.
- a light chain polypeptide gene having a base sequence in which the numbers 811 to 1134) were replaced was prepared, and a light chain polypeptide GS vector was prepared in the same manner as the tandem form a light chain polypeptide vector.
- a bispecific antibody was expressed in the same manner as in tandem form a to obtain a purified tandem form b antibody.
- tandem foam c A light chain polypeptide in which a linker sequence (consisting of amino acid sequences from amino acid numbers 215 to 270 of SEQ ID NO: 4) is replaced with ((Gly) 4 Ser) 3 in a light chain polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 is used.
- a reference bispecific antibody (referred to as tandem form c) was made using a method similar to that for tandem form a.
- FIG. 2 shows the results of reducing SDS-PAGE of purified antibodies of tandem forms a and c.
- tandem form a the light chain polypeptide was cleaved by intracellular protease and separated into the light chain of the anti-human TLR2 antibody and the light chain of the anti-human TLR4 antibody (bands 3 and 4 in FIG. 2).
- tandem form c does not contain a protease recognition site in the linker between light chains, it was expressed with both light chains linked (band 2 in FIG. 2).
- tandem form d ⁇ Preparation of tandem foam d> The same method as in tandem form b, except that the light chain polypeptide in which the linker sequence (consisting of the amino acid sequence of SEQ ID NO: 9) is replaced with ((Gly) 4 Ser) 3 in the light chain polypeptide of tandem form b was used to generate a reference bispecific antibody (referred to as tandem form d).
- DVD-Ig Form b As a reference antibody, a DVD-Ig type bispecific antibody (referred to as DVD-Ig Form b) was prepared. As the variable regions of the anti-human TLR4 antibody portion and the anti-human TLR2 antibody portion in the bispecific antibody, the same variable regions as those used in tandem form b were used, and the heavy and light chain constant regions were , Human Ig ⁇ 1 constant region and human Ig ⁇ constant region were used, respectively. As a culture and purification method, the same method as in tandem foam b was used to obtain each purified antibody.
- Non-Patent Document 1 the heavy chain variable region and the light chain variable region of the anti-human TLR4 antibody were linked to the N-terminals of the heavy chain and light chain of the anti-human TLR2 antibody via a linker, respectively.
- a DVD-Ig type bispecific antibody was produced (FIG. 1, referred to as DVD-Ig Form b).
- the heavy chain linker the same linker used in the heavy chain of tandem form a was used.
- As the light chain linker a linker consisting of the amino acid sequence shown in SEQ ID NO: 13 which is a precision protease recognition sequence was used.
- the purified antibody was enzyme-treated with a protease reaction solution (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, Precision protease (GE Healthcare Japan) 5 units). After the enzyme treatment, the protease was removed with Glutathione Sepharose carrier (GE Healthcare Japan) and used in Example 10.
- a protease reaction solution 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, Precision protease (GE Healthcare Japan) 5 units. After the enzyme treatment, the protease was removed with Glutathione Sepharose carrier (GE Healthcare Japan) and used in Example 10.
- TLR2-IgG immunoglobulin G
- TLR4-IgG anti-human TLR4 antibody
- TLR2-IgG heavy chain containing the heavy chain variable region and human Ig ⁇ 1 constant region of anti-human TLR2 antibody used in tandem form a
- TLR4-IgG light chain variable region and human Ig ⁇ constant region of anti-human TLR2 antibody used in tandem form a IgG antibody comprising a light chain comprising:
- TLR4-IgG a heavy chain comprising a heavy chain variable region and a human Ig ⁇ 1 constant region of an anti-human TLR4 antibody used in tandem form a
- GS vector into which the heavy chain and the light chain of each antibody were inserted was prepared, and both heavy chain and light chain expression vectors were constructed from each GS vector.
- a culture and purification method the same method as in tandem foam a was used to obtain each purified antibody.
- Example 2 Evaluation of binding activity to human TLR4-tandem form a
- Example 2 Evaluation of binding activity to human TLR4-tandem form a
- cell ELISA was performed. Carried out. Tandem form c and TLR4-IgG were used as reference antibodies.
- Human TLR4 / MD2-expressing HEK293 cells are seeded at 1 ⁇ 10 4 cells / well in a BD BioCoat poly D-lysine 384-well plate (Becton Dickinson) using ⁇ -MEM medium (Life Technologies) and cultured overnight. did.
- the medium is discarded the next day and diluted with a 1% bovine serum-derived albumin (BSA) and 10 mM 2- [4- (2-hydroxyethyl) -1-piperazinyl] -ethanesulfonic acid (HEPES) -containing Hanks buffered salt solution.
- BSA bovine serum-derived albumin
- HEPES 2- [4- (2-hydroxyethyl) -1-piperazinyl] -ethanesulfonic acid
- Diluted solutions of each diluted antibody (tandem form a, tandem form c, or TLR4-IgG) (tandem forms a and c are in the concentration range from 100 nM to 0.00005 nM final concentration, and TLR4-IgG is from 99 nM to 0 final concentration).
- Example 3 Evaluation of binding activity to human TLR2-tandem form a
- SPR analysis was performed. Tandem form c and TLR2-IgG were used as reference antibodies.
- Biacore T200 GE Healthcare Japan
- Anti-His IgG attached to His Capture Kit
- His Capture Kit GE Healthcare Japan, 28-9950-56
- Amine Coupling Kit GE Healthcare Japan, BR-1000-50
- HBS-EP + buffer GE Healthcare Japan, BR-1006-69.
- Human TLR2 protein R & D systems, 2616TR / CF
- HBS-EP + buffer 8-step dilution series having a common ratio of 2 in a concentration range of final concentration from 100 nM to 0.781 nM)
- HBS-EP + buffer 8-step dilution series having a common ratio of 2 in a concentration range of final concentration from 100 nM to 0.781 nM
- HBS-EP + buffer was added at a flow rate of 50 ⁇ L / min for 5 minutes, and the dissociation of the purified antibody and human TLR2 was measured. Analyzes Bivalent analyte model, the Rmax in Fit local, association rate constant (k a) and calculates the dissociation rate constant (k d), the k d was calculated binding a dissociation constant (K D) of dividing by k a .
- tandem form a was prepared by expressing in CHO-K1SV cells instead of Expi293 cells. Specifically, with respect to CD-CHO medium (Life Technologies) in about 1 ⁇ 10 7 cells / mL in the culture the CHO-K1SV cells (Lonza, Inc.), in tandem form a described in Example 1 Weight Both chain and light chain expression vectors were transfected using electroporation and cultured for 7 days. The culture supernatant was purified using a protein A or protein G column (GE Healthcare Japan) to obtain a purified antibody.
- CD-CHO medium Life Technologies
- CHO-K1SV cells Longza, Inc.
- tandem form a expressed in Expi293 cells has a concentration range of 42 nM to 0.00002 nM
- tandem form a expressed in CHO-K1SV cells has a final concentration of 35 nM to 0.00002 nM. Each area was evaluated.
- Example 5 Evaluation of neutralizing activity against human TLR4-tandem form a
- U937 cells which are human monocytic cells that endogenously express human TLR4 / MD2
- LPS Polysaccharide
- Tandem form c and TLR4-IgG were used as reference antibodies.
- the culture supernatant was collected, and the human IL-6 concentration contained in the culture supernatant was determined using EnVision (registered trademark) (Perkin Elmer) using a commercially available AlphaLISA (registered trademark) kit (Thermo Scientific). Measured at The 50% inhibitory concentration (IC 50 ) of each antibody was calculated from 4-parameter logistic curve regression using statistical analysis software GraphPad Prism (GraphPad Software) using the obtained measurement results.
- Example 6 Evaluation of neutralizing activity against human TLR2-tandem form a
- U937 cells which are human monocytic cells that endogenously express human TLR2
- a -6 production inhibition assay was performed. Tandem form c and TLR2-IgG were used as reference antibodies.
- U937 cells (ATCC: CRL-1593.2) were placed in RPMI 1640 medium (life) at 30 ⁇ L / well in a 384 well plate (Thermo Scientific) to 2 ⁇ 10 4 cells / well 2 days before the experiment. Seeds under Technology).
- PMA phorbol ester (Funakoshi, PE-160)) was added to the medium to a final concentration of 100 nM.
- a diluted solution of the purified antibody (tandem form a, tandem form c, or TLR2-IgG) diluted in the medium (tandem forms a and c are in the concentration range from 20 nM to 0.00001 nM, and TLR2-IgG is the final concentration.
- Example 7 Production of antibodies using various protease recognition sequences and evaluation of binding activity-tandem form a
- the protease recognition sequence (SEQ ID NO: 5) in the linker of the light chain polypeptide was changed to various intracellular protease recognition sequences (SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: Tandem foam a was prepared using three types of linkers (SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12, respectively) replaced with 8).
- SDS-PAGE was performed on the tandem foam a produced in this example.
- the binding activity against human TLR4 was evaluated using the method described in Example 2. However, the dilution series of each purified antibody was evaluated in a concentration range of 42 nM to 0.00002 nM.
- Fig. 3 shows the result of reduced SDS-PAGE.
- the light chain polypeptide linker is cleaved by intracellular protease, and the anti-human TLR2 antibody light chain and anti-human TLR4 antibody It was divided into light chains.
- Table 6 shows the results of the binding activity of each antibody expressed in Expi293 cells to human TLR4. When any protease recognition sequence was used as the linker between the light chains, the antigen-binding activity of the inner anti-human TLR4 antibody portion was maintained. Table 6: Binding activity to human TLR4
- Example 8 Evaluation of neutralizing activity against human TLR4-tandem form b
- Example 1 bispecific antibody format having an anti-human TLR4 antibody portion on the outside and an anti-human TLR2 antibody portion on the inside
- the LPS-induced IL-6 production inhibition assay used in 5 was performed.
- the protease recognition sequence (SEQ ID NO: 5) in the linker of the light chain polypeptide was changed to various intracellular protease recognition sequences (SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: Tandem form b produced in CHO-K1SV cells using the three types of linkers (SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12, respectively) replaced with 8) was used. Tandem form d and TLR4-IgG were used as reference antibodies. Regarding the final concentration of the test antibody, the test was performed in a concentration range of 20 nM to 0.00001 nM.
- Example 9 Evaluation of neutralizing activity against human TLR2-tandem form b
- the Pam2CSK4-induced IL-6 production inhibition assay used in Example 6 was performed.
- Tandem form d and TLR2-IgG were used as reference antibodies.
- the final concentration of the test antibody tandem form b and tandem form d were performed in a final concentration range of 20 nM to 0.00001 nM, and TLR2-IgG was performed in a final concentration range of 19 nM to 0.00001 nM.
- Example 10 Structural stability of bispecific antibody
- Tm value thermal denaturation intermediate temperature
- DSC differential scanning calorimetry
- Tm1 is a Tm value confirmed only for the DVD-Ig form b, and is caused by a structural change in the first variable region (VH (1) and VL (1)) of the DVD-Ig form b.
- Tm2 of the tandem form b includes a first variable region, a CH1 region and a CL region on the C-terminal side of the first variable region, a second variable region (VH (2), VL (2)), and a second variable region. This is a Tm value resulting from a change in the structure consisting of the CH1 and CL regions on the C-terminal side of the region, and the CH2 region.
- Tm2 of the DVD-Ig form b is a Tm value resulting from a change in the structure of the second variable region, the CH1 region and the CL region on the C-terminal side of the second variable region, and the CH2 region.
- Tm3 is a Tm value resulting from a change in the structure of the CH3 region of each antibody.
- DVD-Ig form b undergoes structural changes in the variable region at low temperatures and is structurally unstable, whereas tandem form b is stable at higher temperatures and the bispecific antibody of the present invention However, it was found to be more stable against heat than the bispecific antibody of the DVD-Ig type.
- Table 8 DSC test results
- the bispecific antibody of the novel format of the present invention retains high binding ability to both antigens and can be expected to be efficiently produced in a commercial production process. For example, it is useful for research and development and commercial production of bispecific antibodies for various treatments.
- the base sequence shown in SEQ ID NO: 1 in the sequence listing is the base sequence of the heavy chain of tandem form a
- the amino acid sequence shown in SEQ ID NO: 2 is the amino acid sequence encoded by SEQ ID NO: 1.
- the base sequence shown in SEQ ID NO: 3 in the sequence listing is the base sequence of the light chain fragment of tandem form a
- the amino acid sequence shown in SEQ ID NO: 4 is the amino acid sequence encoded by SEQ ID NO: 3.
- the amino acid sequences shown in SEQ ID NOs: 5, 6, 7, and 8 in the sequence listing are protease recognition sequences.
- the amino acid sequences shown in SEQ ID NOs: 9, 10, 11, and 12 in the sequence listing are linker sequences in the light chain polypeptide.
- the amino acid sequence shown in SEQ ID NO: 13 in the sequence listing is a precision protease recognition sequence.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]二重特異的抗体であって、該二重特異的抗体は、2つの重鎖、2つの第1の軽鎖、及び2つの第2の軽鎖を含み、
該重鎖は、それぞれアミノ末端側から順に、第1の重鎖可変領域、CH1領域、第1のリンカー、第2の重鎖可変領域、及び重鎖定常領域を含み、
該第1の軽鎖は、それぞれアミノ末端側から順に、第1の軽鎖可変領域及び第1の軽鎖定常領域を含み、
該第2の軽鎖は、それぞれアミノ末端側から順に、第2の軽鎖可変領域及び第2の軽鎖定常領域を含み、
該第1の重鎖可変領域と該第1の軽鎖可変領域は、第1の抗原結合部位を形成し、
該第2の重鎖可変領域と該第2の軽鎖可変領域は、第2の抗原結合部位を形成し、
該第1の抗原結合部位及び該第2の抗原結合部位は互いに異なる抗原を認識する、
二重特異的抗体。
[2]以下のa)~c):
a)[1]に記載の二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
b)[1]に記載の二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
c)[1]に記載の二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、並びに、該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞
から選択される、宿主細胞であって、
ここで、該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドは、該第1の軽鎖のカルボキシ末端に第2のリンカーを介して該第2の軽鎖のアミノ末端が連結されたポリペプチドをコードする塩基配列を含み、該第2のリンカーはプロテアーゼ認識配列を含むペプチドリンカーである、
宿主細胞。
[3]第2のリンカーが細胞内プロテアーゼ認識配列を含むペプチドリンカーである、[2]に記載の宿主細胞。
[4]二重特異的抗体を生産する方法であって、[2]に記載の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、方法。
[5][4]に記載の方法によって生産できる二重特異的抗体。
[6]二重特異的抗体を生産する方法であって、[3]に記載の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、方法。
[7]培養工程において宿主細胞内のプロテアーゼによって第2のリンカーが切断される、[6]に記載の方法。
[8][6]又は[7]に記載の方法によって生産できる二重特異的抗体。
[9][1]に記載の二重特異的抗体の抗原結合フラグメント。
[10]Fab、Fab’、又はF(ab’)2である[9]に記載の抗原結合フラグメント。
[11]二重特異的抗体であって、該二重特異的抗体は、2つの軽鎖、2つの第1の重鎖のフラグメント、及び2つの第2の重鎖を含み、
該軽鎖は、それぞれアミノ末端側から順に、第1の軽鎖可変領域、第1の軽鎖定常領域、第1のリンカー、第2の軽鎖可変領域、及び第2の軽鎖定常領域を含み、
該第1の重鎖のフラグメントは、それぞれアミノ末端側から順に、第1の重鎖可変領域及びCH1領域を含み、
該第2の重鎖は、それぞれアミノ末端側から順に、第2の重鎖可変領域及び重鎖定常領域を含み、
該第1の重鎖可変領域と該第1の軽鎖可変領域は、第1の抗原結合部位を形成し、
該第2の重鎖可変領域と該第2の軽鎖可変領域は、第2の抗原結合部位を形成し、
該第1の抗原結合部位及び該第2の抗原結合部位は互いに異なる抗原を認識する、
二重特異的抗体。
[12]以下のa)~c):
a)[11]に記載の二重特異的抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドと該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
b)[11]に記載の二重特異的抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
c)[11]に記載の二重特異的抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、並びに、該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞
から選択される、宿主細胞であって、
ここで、該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドは、該第1の重鎖のフラグメントのカルボキシ末端に第2のリンカーを介して該第2の重鎖のアミノ末端が連結されたポリペプチドをコードする塩基配列を含み、該第2のリンカーはプロテアーゼ認識配列を含むペプチドリンカーである、
宿主細胞。
[13]第2のリンカーが細胞内プロテアーゼ認識配列を含むペプチドリンカーである、[12]に記載の宿主細胞。
[14]二重特異的抗体を生産する方法であって、[12]に記載の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、方法。
[15][14]に記載の方法によって生産できる二重特異的抗体。
[16]二重特異的抗体を生産する方法であって、[13]に記載の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、方法。
[17]培養工程において宿主細胞内のプロテアーゼによって第2のリンカーが切断される、[16]に記載の方法。
[18][16]又は[17]に記載の方法によって生産できる二重特異的抗体。
[19][11]に記載の二重特異的抗体の抗原結合フラグメント。
[20]Fab、Fab’、又はF(ab’)2である[19]に記載の抗原結合フラグメント。
本発明の二重特異的抗体には、以下の(1)及び(2)に記載の二重特異的抗体が含まれる:
(1)重鎖連結二重特異的抗体
二重特異的抗体であって、該二重特異的抗体は、2つの重鎖、2つの第1の軽鎖、及び2つの第2の軽鎖を含み、
該重鎖は、それぞれアミノ末端側から順に、第1の重鎖可変領域、CH1領域、第1のリンカー、第2の重鎖可変領域、及び重鎖定常領域を含み、
該第1の軽鎖は、それぞれアミノ末端側から順に、第1の軽鎖可変領域及び第1の軽鎖定常領域を含み、
該第2の軽鎖は、それぞれアミノ末端側から順に、第2の軽鎖可変領域及び第2の軽鎖定常領域を含み、
該第1の重鎖可変領域と該第1の軽鎖可変領域は、第1の抗原結合部位を形成し、
該第2の重鎖可変領域と該第2の軽鎖可変領域は、第2の抗原結合部位を形成し、
該第1の抗原結合部位及び該第2の抗原結合部位は互いに異なる抗原を認識する、
二重特異的抗体。
(2)軽鎖連結二重特異的抗体
二重特異的抗体であって、該二重特異的抗体は、2つの軽鎖、2つの第1の重鎖のフラグメント、及び2つの第2の重鎖を含み、
該軽鎖は、それぞれアミノ末端側から順に、第1の軽鎖可変領域、第1の軽鎖定常領域、第1のリンカー、第2の軽鎖可変領域、及び第2の軽鎖定常領域を含み、
該第1の重鎖のフラグメントは、それぞれアミノ末端側から順に、第1の重鎖可変領域及びCH1領域を含み、
該第2の重鎖は、それぞれアミノ末端側から順に、第2の重鎖可変領域及び重鎖定常領域を含み、
該第1の重鎖可変領域と該第1の軽鎖可変領域は、第1の抗原結合部位を形成し、
該第2の重鎖可変領域と該第2の軽鎖可変領域は、第2の抗原結合部位を形成し、
該第1の抗原結合部位及び該第2の抗原結合部位は互いに異なる抗原を認識する、
二重特異的抗体。
本発明の宿主細胞には、以下の特徴を有する宿主細胞が含まれる:
(1)重鎖連結二重特異的抗体を作製するための宿主細胞
以下のa)~c):
a)重鎖連結二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
b)重鎖連結二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
c)重鎖連結二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、並びに、該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞
から選択される、宿主細胞であって、
ここで、該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドは、該第1の軽鎖のカルボキシ末端に第2のリンカーを介して該第2の軽鎖のアミノ末端が連結されたポリペプチドをコードする塩基配列を含み、該第2のリンカーはプロテアーゼ認識配列を含むペプチドリンカーである、
宿主細胞。
(2)軽鎖連結二重特異的抗体を作製するための宿主細胞
以下のa)~c):
a)軽鎖連結二重特異的抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドと該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
b)軽鎖連結二重特異的抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
c)軽鎖連結二重特異的抗体の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、並びに、該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞
から選択される、宿主細胞であって、
ここで、該二重特異的抗体の第1の重鎖のフラグメント及び第2の重鎖をコードする塩基配列を含むポリヌクレオチドは、該第1の重鎖のフラグメントのカルボキシ末端に第2のリンカーを介して該第2の重鎖のアミノ末端が連結されたポリペプチドをコードする塩基配列を含み、該第2のリンカーはプロテアーゼ認識配列を含むペプチドリンカーである、
宿主細胞。
本発明の二重特異的抗体を生産する方法には、本発明の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、二重特異的抗体を生産する方法が含まれる。
本実施例では、本発明の二重特異的抗体として以下の2種類の二重特異的抗体を作製した。
1)抗ヒトTLR4抗体の重鎖のN末端側に抗ヒトTLR2抗体の重鎖可変領域及びCH1領域をリンカーを介して連結した重鎖、抗ヒトTLR2抗体の軽鎖、及び抗ヒトTLR4抗体の軽鎖を含む二重特異的抗体(図1、タンデムフォームaと称する);並びに
2)タンデムフォームaの抗ヒトTLR2抗体の重鎖可変領域及び軽鎖可変領域と抗ヒトTLR4抗体の重鎖可変領域及び軽鎖可変領域をそれぞれ置き換えた二重特異的抗体(図1、タンデムフォームbと称する)
二重特異的抗体の重鎖をコードする遺伝子の5’側にシグナル配列(Protein.,Eng.,Vol.1,No.6,p.499,1987)をコードする遺伝子を繋げ、この重鎖遺伝子をGSベクターpEE6.4(Lonza社)に挿入した。この二重特異的抗体の重鎖の塩基配列を配列番号1に、それによりコードされるアミノ酸配列を配列番号2に示す。配列番号2のアミノ酸番号1から117までのアミノ酸配列からなる領域は、抗ヒトTLR2抗体の重鎖可変領域である。配列番号2のアミノ酸番号118から221までのアミノ酸配列からなる領域は、ヒトIgγ1のCH1領域である。配列番号2のアミノ酸番号222から236までのアミノ酸配列からなる領域は、リンカー配列である。配列番号2のアミノ酸番号237から355までのアミノ酸配列からなる領域は、抗ヒトTLR4抗体の重鎖可変領域である。配列番号2のアミノ酸番号356から685までのアミノ酸配列からなる領域は、ヒトIgγ1の重鎖定常領域である。
配列番号1に示される塩基配列において抗ヒトTLR2抗体の重鎖可変領域をコードする部分(配列番号1の塩基番号1から351まで)と抗ヒトTLR4抗体の重鎖可変領域(配列番号1の塩基番号709から1065まで)を置き換えた塩基配列を有する重鎖遺伝子を作製し、タンデムフォームaの重鎖ベクターと同様にして重鎖のGSベクターを作製した。配列番号3に示される塩基配列において抗ヒトTLR2抗体の軽鎖をコードする部分(配列番号3の塩基番号1から324まで)と抗ヒトTLR4抗体の軽鎖をコードする部分(配列番号3の塩基番号811から1134まで)を置き換えた塩基配列を有する軽鎖ポリペプチド遺伝子を作製し、タンデムフォームaの軽鎖ポリペプチドベクターと同様にして軽鎖ポリペプチドのGSベクターを作製した。両GSベクターを用いて、タンデムフォームaと同様の方法で二重特異的抗体を発現させ、タンデムフォームbの精製抗体を得た。
配列番号4のアミノ酸配列からなる軽鎖ポリペプチドにおいてリンカー配列(配列番号4のアミノ酸番号215から270までのアミノ酸配列からなる)を((Gly)4Ser)3に置換した軽鎖ポリペプチドを用いることを除き、タンデムフォームaと同様の方法を用いて、参照の二重特異的抗体(タンデムフォームcと称する)を作製した。
タンデムフォームbの軽鎖ポリペプチドにおいてリンカー配列(配列番号9のアミノ酸配列からなる)を((Gly)4Ser)3に置換した軽鎖ポリペプチドを用いることを除き、タンデムフォームbと同様の方法を用いて、参照の二重特異的抗体(タンデムフォームdと称する)を作製した。
<DVD-Igフォームb>
参照抗体として、DVD-Ig型の二重特異的抗体(DVD-Igフォームbと称する)を作製した。該二重特異的抗体における抗ヒトTLR4抗体部分及び抗ヒトTLR2抗体部分の可変領域としては、タンデムフォームbで用いた各可変領域と同じ可変領域を用い、重鎖及び軽鎖の定常領域としては、それぞれヒトIgγ1定常領域及びヒトIgκ定常領域を用いた。培養及び精製方法としてはタンデムフォームbと同様の方法を用い、各精製抗体を得た。
参照抗体として、以下のIgG型の抗ヒトTLR2抗体(TLR2-IgGと称する)及び抗ヒトTLR4抗体(TLR4-IgGと称する)を作製した。
TLR2-IgG:タンデムフォームaで用いた抗ヒトTLR2抗体の重鎖可変領域及びヒトIgγ1定常領域を含む重鎖、並びにタンデムフォームaで用いた抗ヒトTLR2抗体の軽鎖可変領域及びヒトIgκ定常領域を含む軽鎖を含む、IgG抗体
TLR4-IgG:タンデムフォームaで用いた抗ヒトTLR4抗体の重鎖可変領域及びヒトIgγ1定常領域を含む重鎖、並びにタンデムフォームaで用いた抗ヒトTLR4抗体の軽鎖可変領域及びヒトIgκ定常領域を含む軽鎖を含む、IgG抗体
実施例1で作製したタンデムフォームa(外側に抗ヒトTLR2抗体部分を、内側に抗ヒトTLR4抗体部分を有する二重特異的抗体フォーマット)のヒトTLR4に対する結合活性を評価するために、細胞ELISAを実施した。参照抗体として、タンデムフォームc及びTLR4-IgGを用いた。ヒトTLR4/MD2発現HEK293細胞を、1×104cells/ウェルでBD BioCoat ポリD-リジン384ウェルプレート(ベクトンディッキンソン社)にα-MEM培地(ライフテクノロジーズ社)を用いて播種し、一晩培養した。翌日培地を捨てて、希釈液(1%ウシ血清由来アルブミン(BSA)及び10mM 2-[4-(2-ヒドロキシエチル)-1-ピペラジニル]-エタンスルホン酸(HEPES)含有ハンクス緩衝塩溶液)で希釈した各精製抗体(タンデムフォームa、タンデムフォームc、又はTLR4-IgG)の希釈溶液(タンデムフォームa及びcは最終濃度100nMから0.00005nMの濃度域で、TLR4-IgGは最終濃度99nMから0.00005nMの濃度域で、それぞれ公比5倍の10段階希釈系列)を30μL添加した。37℃にて1時間培養した後、洗浄液(0.1%BSA及び10mM HEPES含有ハンクス緩衝塩溶液)にて洗浄し、洗浄液で5000倍に希釈したホースラディッシュぺルオキシダーゼ標識抗ヒトIgG抗体(DAKO社)を添加した。37℃にて1時間培養した後、洗浄液で洗浄し、呈色試薬であるTMB(MOSS社)25μLを加えた。20分後に1M硫酸25μLを添加して呈色反応を停止させ、その呈色強度をSafire II(テカン社)で測定することで、抗体の結合活性を評価した。得られた測定結果を用いて統計解析ソフトGraphPad Prism(GraphPad Software社)による4パラメータロジスティック曲線回帰から、各抗体の50%効果濃度(EC50)を算出した。
表1:ヒトTLR4に対する結合活性
実施例1で作製したタンデムフォームaのヒトTLR2への結合活性を評価するために、SPR解析を実施した。参照抗体として、タンデムフォームc及びTLR2-IgGを用いた。SPR解析においては、Biacore T200(GEヘルスケアジャパン社)を用いた。CM5センサーチップにHis Capture Kit(GEヘルスケアジャパン社、28-9950-56)とAmine Coupling Kit(GEヘルスケアジャパン社、BR-1000-50)を用いてAnti-His IgG(His Capture Kit付属)を固定した。流路No.1をリファレンスとし、この流路にはヒトTLR2蛋白質を結合させず、その他の流路(No.2)に、HBS-EP+ buffer(GEヘルスケアジャパン社、BR-1006-69)で0.66μg/mLに希釈したヒトTLR2蛋白質(R&D systems社、2616TR/CF)を流速5μL/分にて2分間添加し固相化させた。その後、各精製抗体(タンデムフォームa、タンデムフォームc、又はTLR2-IgG)をHBS-EP+ bufferで系列希釈した溶液(最終濃度100nMから0.781nMの濃度域で公比2倍の8段階希釈系列)を、流速50μL/分にて2分間添加し、精製抗体とTLR2の結合を測定した。次に、HBS-EP+ bufferを流速50μL/分にて5分間添加し、精製抗体とヒトTLR2の解離を測定した。Bivalent analyte model、RmaxをFit localで解析し、結合速度定数(ka)及び解離速度定数(kd)を算出し、kdをkaで割ることによって結合解離定数(KD)を算出した。
表2:ヒトTLR2に対する結合活性
実施例1のタンデムフォームaの作製において、Expi293細胞に代えてCHO-K1SV細胞で発現させることにより、タンデムフォームaを作製した。具体的には、CD-CHO medium(ライフテクノロジーズ社)で約1×107cells/mLに培養されたCHO-K1SV細胞(Lonza社)に対して、実施例1に記載のタンデムフォームaの重鎖及び軽鎖の両発現ベクターをエレクトロポレーション法を用いてトランスフェクトし、7日間培養した。培養上清をプロテインA又はプロテインGカラム(GEヘルスケアジャパン社)を用いて精製し、精製抗体を得た。
実施例4で作製したタンデムフォームaのヒトTLR4に対する中和活性を評価するために、ヒトTLR4/MD2を内在的に発現するヒト単球系細胞であるU937細胞を用いて、TLR4リガンドであるリポポリサッカライド(LPS)誘発IL-6産生阻害アッセイを実施した。参照抗体として、タンデムフォームc及びTLR4-IgGを用いた。
表4:ヒトTLR4に対する中和活性
実施例4で作製したタンデムフォームaのヒトTLR2に対する中和活性を評価するために、ヒトTLR2を内在的に発現するヒト単球系細胞であるU937細胞を用いて、TLR2リガンドであるPam2CSK4誘発IL-6産生阻害アッセイを実施した。参照抗体として、タンデムフォームc及びTLR2-IgGを用いた。
実施例1及び実施例4のタンデムフォームaの作製において、軽鎖ポリペプチドのリンカー中のプロテアーゼ認識配列(配列番号5)を各種細胞内プロテアーゼ認識配列(配列番号6、配列番号7、又は配列番号8)に置き換えた3種類のリンカー(それぞれ、配列番号10、配列番号11、又は配列番号12)を用いて、タンデムフォームaを作製した。本実施例で作製したタンデムフォームaについて、SDS-PAGEを実施した。さらに実施例2に記載の方法を用いてヒトTLR4に対する結合活性を評価した。但し、各精製抗体の希釈系列は、42nMから0.00002nMの濃度域で評価した。
表6:ヒトTLR4に対する結合活性
実施例1で作製したタンデムフォームb(外側に抗ヒトTLR4抗体部分を、内側に抗ヒトTLR2抗体部分を有する二重特異的抗体フォーマット)のヒトTLR4に対する中和活性を評価するために、実施例5で用いたLPS誘発IL-6産生阻害アッセイを実施した。被験抗体として、実施例1のタンデムフォームbの作製において、軽鎖ポリペプチドのリンカー中のプロテアーゼ認識配列(配列番号5)を各種細胞内プロテアーゼ認識配列(配列番号6、配列番号7、又は配列番号8)に置き換えた3種類のリンカー(それぞれ、配列番号10、配列番号11、又は配列番号12)を用いて、CHO-K1SV細胞で作製したタンデムフォームbを使用した。参照抗体として、タンデムフォームd及びTLR4-IgGを用いた。被験抗体の最終濃度に関して、最終濃度20nMから0.00001nMの濃度域でそれぞれ実施した。
表7:ヒトTLR4に対する中和活性
実施例8で作製したタンデムフォームbのヒトTLR2に対する中和活性を評価するために、実施例6で用いたPam2CSK4誘発IL-6産生阻害アッセイを実施した。参照抗体として、タンデムフォームd及びTLR2-IgGを用いた。被験抗体の最終濃度に関して、タンデムフォームb及びタンデムフォームdは最終濃度20nMから0.00001nMの濃度域で、TLR2-IgGは最終濃度19nMから0.00001nMの濃度域でそれぞれ実施した。
本発明の二重特異的抗体の可変領域における構造安定性を評価するために、示差走査熱量測定(Differential Scanning Calorimetry(DSC))による熱変性中間温度(Tm値)の評価を行った。タンデムフォームb及びDVD-Igフォームbの精製抗体を、20mM クエン酸及び120mM NaCl(pH6.0)の溶液で濃縮カセットVivapore5(Sartorius AG社)を用いてバッファー置換を行った。得られた各抗体溶液について、MicroCal VP-Capillary DSC(GEヘルスケアジャパン社)を用いて、約0.12mg/mLの蛋白質で、25℃から100℃まで1℃/分の昇温速度でDSC測定を行った。得られたDSCの変性曲線より、各抗体の可変領域のTm値を解析ソフトOrigin7(OriginLab社)を用いて算出した。
表8:DSC試験の結果
Claims (10)
- 二重特異的抗体であって、該二重特異的抗体は、2つの重鎖、2つの第1の軽鎖、及び2つの第2の軽鎖を含み、
該重鎖は、それぞれアミノ末端側から順に、第1の重鎖可変領域、CH1領域、第1のリンカー、第2の重鎖可変領域、及び重鎖定常領域を含み、
該第1の軽鎖は、それぞれアミノ末端側から順に、第1の軽鎖可変領域及び第1の軽鎖定常領域を含み、
該第2の軽鎖は、それぞれアミノ末端側から順に、第2の軽鎖可変領域及び第2の軽鎖定常領域を含み、
該第1の重鎖可変領域と該第1の軽鎖可変領域は、第1の抗原結合部位を形成し、
該第2の重鎖可変領域と該第2の軽鎖可変領域は、第2の抗原結合部位を形成し、
該第1の抗原結合部位及び該第2の抗原結合部位は互いに異なる抗原を認識する、
二重特異的抗体。 - 以下のa)~c):
a)請求項1に記載の二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドと該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;
b)請求項1に記載の二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターと該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞;並びに
c)請求項1に記載の二重特異的抗体の重鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞、並びに、該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドを含む発現ベクターで形質転換された宿主細胞
から選択される、宿主細胞であって、
ここで、該二重特異的抗体の第1の軽鎖及び第2の軽鎖をコードする塩基配列を含むポリヌクレオチドは、該第1の軽鎖のカルボキシ末端に第2のリンカーを介して該第2の軽鎖のアミノ末端が連結されたポリペプチドをコードする塩基配列を含み、該第2のリンカーはプロテアーゼ認識配列を含むペプチドリンカーである、
宿主細胞。 - 第2のリンカーが細胞内プロテアーゼ認識配列を含むペプチドリンカーである、請求項2に記載の宿主細胞。
- 二重特異的抗体を生産する方法であって、請求項2に記載の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、方法。
- 請求項4に記載の方法によって生産できる二重特異的抗体。
- 二重特異的抗体を生産する方法であって、請求項3に記載の宿主細胞を培養し、二重特異的抗体を発現させる工程を包含する、方法。
- 培養工程において宿主細胞内のプロテアーゼによって第2のペプチドリンカーが切断される、請求項6に記載の方法。
- 請求項6又は7に記載の方法によって生産できる二重特異的抗体。
- 請求項1に記載の二重特異的抗体の抗原結合フラグメント。
- Fab、Fab’、又はF(ab’)2である請求項9に記載の抗原結合フラグメント。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15861801.7A EP3222637A4 (en) | 2014-11-21 | 2015-11-20 | Novel bispecific antibody format |
JP2016560297A JP6686897B2 (ja) | 2014-11-21 | 2015-11-20 | 新規二重特異的抗体フォーマット |
US15/528,131 US10927185B2 (en) | 2014-11-21 | 2015-11-20 | Bispecific antibody format |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-237172 | 2014-11-21 | ||
JP2014237172 | 2014-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016080510A1 true WO2016080510A1 (ja) | 2016-05-26 |
Family
ID=56014042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/082653 WO2016080510A1 (ja) | 2014-11-21 | 2015-11-20 | 新規二重特異的抗体フォーマット |
Country Status (4)
Country | Link |
---|---|
US (1) | US10927185B2 (ja) |
EP (1) | EP3222637A4 (ja) |
JP (1) | JP6686897B2 (ja) |
WO (1) | WO2016080510A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531588A (ja) * | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
JP2008538926A (ja) * | 2005-04-26 | 2008-11-13 | グライコフィ, インコーポレイテッド | 切断可能なリンカーを有する一本鎖抗体 |
JP2012510821A (ja) * | 2008-12-04 | 2012-05-17 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
JP2012530088A (ja) * | 2009-06-16 | 2012-11-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗原結合タンパク質 |
WO2013006544A1 (en) * | 2011-07-06 | 2013-01-10 | Medimmune, Llc | Methods for making multimeric polypeptides |
WO2013119966A2 (en) * | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
JP2013538204A (ja) * | 2010-08-24 | 2013-10-10 | ロシュ グリクアート アーゲー | 活性化可能な二重特異性抗体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
MX342135B (es) | 2011-03-17 | 2016-09-14 | Ramot At Tel-Aviv Univ Ltd | Anticuerpos asimetricos, biespecificos y monoespecificos, y metodos para generar los mismos. |
-
2015
- 2015-11-20 US US15/528,131 patent/US10927185B2/en active Active
- 2015-11-20 JP JP2016560297A patent/JP6686897B2/ja active Active
- 2015-11-20 EP EP15861801.7A patent/EP3222637A4/en active Pending
- 2015-11-20 WO PCT/JP2015/082653 patent/WO2016080510A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531588A (ja) * | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
JP2008538926A (ja) * | 2005-04-26 | 2008-11-13 | グライコフィ, インコーポレイテッド | 切断可能なリンカーを有する一本鎖抗体 |
JP2012510821A (ja) * | 2008-12-04 | 2012-05-17 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
JP2012530088A (ja) * | 2009-06-16 | 2012-11-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗原結合タンパク質 |
JP2013538204A (ja) * | 2010-08-24 | 2013-10-10 | ロシュ グリクアート アーゲー | 活性化可能な二重特異性抗体 |
WO2013006544A1 (en) * | 2011-07-06 | 2013-01-10 | Medimmune, Llc | Methods for making multimeric polypeptides |
WO2013119966A2 (en) * | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
Non-Patent Citations (2)
Title |
---|
MILLER K ET AL.: "Design, construction, and in vitro analyses of multivalent antibodies", J. IMMUNOL., vol. 170, no. 9, 2003, pages 4854 - 4861, XP002508787, ISSN: 1550-6606 * |
See also references of EP3222637A4 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2016080510A1 (ja) | 2017-09-14 |
US20170306053A1 (en) | 2017-10-26 |
JP6686897B2 (ja) | 2020-04-22 |
EP3222637A4 (en) | 2018-10-31 |
EP3222637A1 (en) | 2017-09-27 |
US10927185B2 (en) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240174745A1 (en) | Antibody Constructs for CLDN18.2 and CD3 | |
WO2018110555A1 (ja) | 抗ヒトcd73抗体 | |
CN101896504B (zh) | 二价双特异性抗体 | |
CN102369215B (zh) | 包含全长抗体和单链Fab片段的多特异性抗体 | |
US20150183877A1 (en) | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains | |
TW200932271A (en) | Bivalent, bispecific antibodies | |
US9815891B2 (en) | Monospecific polypeptide reagents | |
JP6215056B2 (ja) | 拮抗性dr3リガンド | |
WO2016010014A1 (ja) | 新規抗ヒトTie2抗体 | |
CN105829534B (zh) | 抗人bdca-2抗体 | |
CN106029884B (zh) | 新型抗人pai-1抗体 | |
KR20200045485A (ko) | 바이러스 오염물을 불활성화하는 방법 | |
JP6686897B2 (ja) | 新規二重特異的抗体フォーマット | |
JP2023518225A (ja) | ムチン17に対する抗体及びその使用 | |
ES2709996T3 (es) | Nuevo anticuerpo biespecífico que se une al TLR2 humano y al TLR4 humano | |
TW202233678A (zh) | 具有增強的剪切特徵的多肽 | |
JP2023547662A (ja) | Cldn6及びcd3に選択的に結合するポリペプチド構築物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15861801 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015861801 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15528131 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016560297 Country of ref document: JP Kind code of ref document: A |